Endometrial cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 4
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

7 of 7+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, United States· US$377,257 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · U01

  Collaborative Modeling to Identify Strategies to Improve US Breast Cancer Outcomes in an Era of Innovation

  University of Wisconsin-Madison· Madison, United States· US$1,839,480 awarded in fiscal year 2026· until Aug 2031

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, United States· US$551,250 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R34

  Reinforcing the Cancer Prevention Potential of Aspirin in Lynch Syndrome (ReCAPP-LS): Development and Piloting of an Electronic Decision Support Tool

  Research Inst of Fox Chase Can Ctr· Philadelphia, United States· US$314,079 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · U01

  Comparative Modeling of Uterine Cancer

  Tufts Medical Center· Boston, United States· US$1,270,995 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours (STP938)

  Step Pharma· Paris, France· EU contribution €2,499,991· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

7 of 152 running projects, newest first. Listed amounts together: US$106.4m + €2.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• Integrative Multi-Omics and Single-Cell Analysis Prioritizes YWHAB Within Ubiquitination-Related Transcriptional Programs in Endometrial Carcinoma.

  Genes (Basel), Oct 2026

• Single-cell sequencing reveals immune networks and metabolic reprogramming in gynecological malignancies.

  Front Immunol, Oct 2026

• Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation.

  Front Immunol, Oct 2026

• Keratin 17 drives endometrial cancer aggressiveness via epithelial-mesenchymal transition: a single-cell transcriptomic and integrative bioinformatics study.

  J Cancer Res Clin Oncol, Aug 2026

• Immune heterogeneity and therapeutic resistance in gynecological malignancies.

  Front Immunol, Jun 2026

• Integrated single-cell and bulk transcriptomics reveals an IGF2BP3-driven metabolic circuitry in endometrial cancer.

  BMC Cancer, Mar 2026

• Detection of pre-transition phases during biological development using single-sample network entropy (SNE).

  NPJ Syst Biol Appl, Nov 2025

• Single-cell landscape of the tumour immune microenvironment in human gynaecologic malignancies.

  Clin Transl Med, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.